awmsg logo



eculizumab (Soliris®)


Reference No. 117

Publication date:
11/06/2009


Appraisal information

eculizumab (Soliris®) 300 mg concentrate for solution for infusion


Company: Alexion Pharma UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 25/03/2009
AWMSG meeting date: 29/04/2009
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0509
Ministerial ratification: 10/06/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Eculizumab (Soliris®) is recommended for restricted use within NHS Wales according to agreed guidelines for the treatment of paroxysmal nocturnal haemoglobinuria. AWMSG is of the opinion that eculizumab (Soliris®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download